This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: sacubitril

Introduction

July 2019 Br J Cardiol 2019;26(suppl1):S3 doi:10.5837/bjc.2019.s01

Introduction

Pardeep S Jhund, John J V McMurray

Abstract

The PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study is the key randomised-controlled trial that underpins the clinical use of sacubitril/valsartan, which demonstrated significantly improved clinical outcomes in patients with HFrEF, in comparison with angiotensin-converting enzyme (ACE) inhibition.1 Patients with HFrEF in the routine-care setting represent a clinically heterogeneous population, with a high incidence of comorbidities. Our first article dives deep into the PARADIGM-HF data, and presents the results of key subgroup analyses that support the use o

| Full text
Sacubitril/valsartan prescribing and community experience in Medway

July 2019 Br J Cardiol 2019;26(suppl 1):S20-S21 doi:10.5837/bjc.2019.s05

Sacubitril/valsartan prescribing and community experience in Medway

Pauline Rouse

Abstract

Introduction Following publication of the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial,1 and being aware of the anticipated National Institute for Health and Care Excellence (NICE) approval of sacubitril/valsartan, this gave the impetus to ensure our patients could have access to this medication as soon as it was NICE approved. Medway has a population of 280,000. The heart failure team at Medway Community Healthcare was established in 2003 and has grown and developed since then as part of the community cardiology team (also providing cardiac rehabilitation

| Full text
Real-world experience and clinical data with sacubitril/valsartan: a Northern Ireland perspective

July 2019 Br J Cardiol 2019;26(suppl 1):S22–S23 doi:10.5837/bjc.2019.s06

Real-world experience and clinical data with sacubitril/valsartan: a Northern Ireland perspective

Edith Donnelly, Carol Patton

Abstract

Background The Southern Health and Social Care Trust (SHSCT) in Northern Ireland has a nurse-led heart failure (HF) service, with seven band 7 heart failure nurse specialists (HFNS) serving a total of about 1,500 patients. All but two of the nurses are non-medical prescribers. The service is community-based with hospital in-reach, with each nurse managing a geographically defined caseload. This model allows patients with HF to be reviewed by a HFNS in either a domiciliary, clinic or acute setting. The nurses have access to, and support from, consultant cardiologists, renal consultants, GPs and a cardiology pharmacist, and also have access to

| Full text

August 2017 Br J Cardiol 2017;24:(3) Online First

BCS 2017: spotlight on heart failure

BJC Staff, Dr Richard Crawley, Dr Brian Halliday, Dr Rosita Zakeri

Abstract

Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now